Tafasitamab and Lenalidomide as First Salvage Therapy for Residual Large B Cell Lym
Phase 2
28
about 2.9 years
18+
1 site in FL
About this study
This trial is testing the safety and effectiveness of tafasitamab and lenalidomide in people with Large B-cell Lymphoma (LBCL) after axicabtagene ciloleucel (axi-cel) treatment. Participants will be asked to spend about 12 months in it.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Lenalidomide
- 2.Take Tafasitamab
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
lenalidomide (Immunomodulatory drug; affects immune system and cancer cells (exact mechanism unclear)), tafasitamab
oral (Oral Capsule)
Primary: Complete Response Rate (CRR)
Secondary: Duration of Response (DoR), Objectives Response Rate (ORR), Progression Free Survival (PFS)